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Purpose: Patient Reported Outcomes (PROs) have become essential clinical trial end points. However, a 
comprehensive, multi-dimensional, patient-relevant and precise glaucoma-specific PRO instrument is not 
available. Therefore, the purpose of this study was to identify content for a new, glaucoma-specific, quality 
of life (QOL) item bank.  
 
Methods: Content identification was undertaken in five phases: 1. Identification of extant items in 
glaucoma-specific instruments and the qualitative literature, 2. Focus groups and interviews with glaucoma 
patients, 3. Item classification and selection, 4. Expert review and revision of items, and 5. Cognitive 
interviews with patients. 
 
Results: A total of 737 unique items (extant items from PRO instruments, 247; qualitative articles, 14 items; 
focus groups and semi-structured interviews, 476 items) were identified. These items were classified into 10 
QOL domains. Four criteria (item redundancy, item inconsistent with domain definition, item content too 
narrow to have wider applicability, and item clarity) were used to remove and refine the items. After the 
cognitive interviews, the final minimally representative item-set had a total of 342 unique items belonging to 
10 domains: activity limitation (88), mobility (20), visual symptoms (19), ocular surface symptoms (22), 
general symptoms (15), convenience (39), health concerns (45), emotional well-being (49), social (23), and 
economic issues (22). 
 
Conclusion: The systematic content identification process identified ten QOL domains which were 
important to patients with glaucoma. The majority of items were identified from the patient-specific focus 
groups and semi-structured interviews suggesting that the existing PRO instruments do not adequately 









Glaucoma is a chronic progressive disease in which optic nerve damage occurs leading to loss of peripheral 
vision; this damage is irreversible and may lead to blindness. The strongest risk factor for glaucoma is 
raised intraocular pressure (IOP), and the main management strategies are early detection and long-term 
IOP reduction with the goal of slowing the progression of the disease.
1
 Glaucoma affects the lives of 
patients in a multitude of ways. Activity limitation tends to affect individuals towards the later stages of the 
disease. However, the disease may affect other areas of a patient’s life from the time of diagnosis. 
Examples include the anxiety of having glaucoma, the inconvenience of instillation of eye drops, frequent 
changes in treatment regimen, treatment side effects, ocular surgery and its potential complications, regular 
hospital or clinic visits, and difficult testing such as visual field testing.
2
 As a result, glaucoma can have a 
significant impact on issues such as, emotional well-being, social relationships, and financial constraints.
3-6
 
Therefore, traditional clinical measures of glaucoma (intraocular pressure, optic nerve head evaluation and 




Over the years, several glaucoma-specific patient-reported outcome (PRO) instruments have been 
developed.
3-5, 8-23
 While these instruments measure various QOL domains such as activity limitation, 
symptoms, convenience of eye-drop use, treatment of side effects and satisfaction; each instrument 
typically measures only one domain.
7, 24
 For instance, the Glaucoma Quality of Life (GQL-15) measures only 
activity limitation,
3, 25
 the Treatment Satisfaction Survey of Intra-ocular Pressure (TSS-IOP) was developed 
to assess treatment satisfaction and side effects of glaucoma medication,
13
 and the Comparison of 





Three instruments [Glaucoma Quality of Life-36 (Glau-QOL-36); Symptoms Impact Glaucoma Score (SIG); 
and a questionnaire by Uenishi et al. 2003
12
] have incorporated multiple QOL domains, but each instrument 
has only a small number of items in each domain.
4, 12, 14
 This is problematic because, as has been frequently 
demonstrated with Rasch analysis, too few items result in inadequate measurement precision.
26-28
 Rasch 
analysis is a psychometric assessment tool, which provides a more comprehensive insight into the 
psychometric properties of a PRO instrument.
29
 Rasch analysis is increasingly being accepted as the 




three glaucoma-specific PROs [Glaucoma Symptom Scale (GSS), Glaucoma Quality of Life (GQL), and 
Glaucoma Symptom Index (GSI)] have been evaluated with Rasch analysis. The GSS was found to have 
unsatisfactory measurement precision.
35
 The GQL was shown to be a sound measure of activity limitation 
albeit with modification.
36
 Similarly, the GSI demonstrated adequate psychometric properties, but is confined 
to measuring activity limitation and symptoms.
20
 Therefore, a comprehensive, precise and valid glaucoma-





A superior option to traditional paper-pencil based PRO instruments is to develop a glaucoma-specific item 
bank. An item bank is a large collection of calibrated items attempting to measure an underlying latent 
trait.
37
 A computer adaptive testing (CAT) system can be used to implement the items from an item bank.
38, 
39
 The CAT system tailors calibrated items from the item bank to individual participants to produce highly 
accurate and precise measurement of QOL.
38, 40
 By implementing items targeted to person ability and thus                                                                                                                                                                                                                             
ential to revolutionize PRO measurement in glaucoma. 
 
Our overarching aim is to develop a comprehensive and multi-domain Rasch scaled PRO in the form of a 
glaucoma-specific item bank. In this paper, we describe the content identification phase of this novel 
glaucoma-specific item bank development process.  
 
Materials and Methods  
A systematic step-wise item identification and review process was used to develop the content of the 
glaucoma-specific item bank which included: identification of extant items in currently available glaucoma-
specific instruments, a qualitative literature review, patient focus groups and semi-structured interviews, 
item classification and selection, expert review and revision of items, and cognitive interviews with patients.  
 
Identification of extant items and literature review 
Rather than developing new items, an initial item pool was created from extant items obtained from 
available glaucoma-specific PRO instruments. An extensive literature review in Entrez Pubmed was carried 
out in May 2011. The key search terms used were ‘glaucoma’ and (‘questionnaire’ or ‘instrument’ or ‘patient 
reported outcome’ or ‘PRO’ or ‘quality of life’ or ‘symptom’ or ‘mobility’ or ‘satisfaction’ or ‘qualitative’). The 
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search was not limited to any time frame or type of PRO instrument. The search identified 1981 papers. 
Reference lists of the papers identified (including review papers) were also scanned manually for additional 
relevant papers. All identified papers were reviewed against the following selection criteria: PRO 
instruments specifically developed for patients with glaucoma, content available in English and developed 
using valid content development methods such as structured/semi-structured interviews and/or literature 
reviews. Nineteen glaucoma-specific PRO instruments fulfilled the selection criteria (Table 1). We also 
included six peer-reviewed articles that reported qualitative research exploring the impact of glaucoma on 
QOL and systematically reviewed them to identify potential concepts that were not covered by extant items.  
 
Focus groups and semi-structured interviews 
Focus groups and semi-structured interviews were used as a supplementary source of item identification to 
our literature review. More importantly, focus groups and semi-structured interviews were used to identify 
important areas of measurement of glaucoma-specific QOL that were not adequately covered by the extant 
items and the qualitative literature review.  
 
Focus group and semi-structured interviews participants  
Participants were specifically selected (purposive sampling) in order to recruit patients with different stages 
of the disease, ethnicity, age, and gender. Patients included were aged 18 years or above, those who had 
glaucoma as a primary diagnosis for at least six months, without other significant eye diseases, able to 
communicate in English, and without any cognitive impairment that could hamper their participation both in 
the group discussion or semi-structured telephone interviews.  
 
Ten focus groups and 19 semi-structured telephone interviews were conducted with glaucoma patients. 
Four focus groups and one telephone interview were conducted at Flinders Medical Centre in South 
Australia, four focus groups and 18 interviews were conducted at the Royal Victorian Eye and Ear Hospital 
in Melbourne, Australia and two focus groups were conducted at centres for glaucoma located in Aberdeen 
and Leeds in the United Kingdom. In total, 72 patients with glaucoma took part in 10 focus groups and 19 
semi-structured individual interviews. Among these, detail demographic data of 58 (80.6%) Australian 
participants were collected. However, demographic data of 14 (19.4%) UK (Leeds and Aberdeen) 
participants were less detailed.    
 6 
Participants were divided into different groups on the basis of glaucoma severity using the Advanced 
Intervention Study (AGIS) visual field classification system.
41
 The grouping was done in order to conduct 
focus groups with the participants having similar levels of the disease severity and also to compare and 
contrast focus groups/interviews data between and within the participants during analysis.  According to the 
AGIS classification, participants’ visual fields are sub-divided into 21 stages of glaucoma severity (0 = none, 
1-5 = mild, 6-11 = moderate, 12-17 = severe and 18-20 = end stage).
41
 These scores were obtained for the 
better eye and the worse eye from the participants’ total deviation plot of Humphrey Visual Field Analyser. 
As the level of glaucoma severity can be different between two eyes, the participants were sub-divided into 
four groups on the basis of the AGIS classification in the better and worse eyes. These groups were, Group 
1: ≤ Mild in better, ≤ moderate in worse; Group 2= ≤ Mild in better, ≤ moderate; Group 3= Moderate in 
better, ≥ Moderate in worse; Group 4 = ≥ Severe (both).  Patients on a range of treatments were also 
included, namely glaucoma topical (drops) therapy, those who had undergone laser, and those who had 
incisional surgery for glaucoma (Table 2). 
 
All the focus groups and interviews were conducted using a topic guide which was prepared based on the 
literature review and clinical experience. The focus groups and interviews were carried out in a semi-
structured format with minimum involvement by the moderator. Informed consent was obtained from all 
participants. Ethical approval was obtained from the Flinders Clinical Research Ethics Committee, Royal 
Victorian Eye and Ear Hospital and the respective collaborative institutions, and the study adhered to the 
tenants of the Declaration of Helsinki.  
 
All interviews were audio recorded and later transcribed verbatim. Thematic data analysis was carried out 
based on the constant comparative method with the assistance of qualitative data analysis software NVivo 
version 9 to sort and code the data.
42, 43
 Specifically, we looked for keywords, phrases, and quotes 
regarding activity limitations, symptoms (visual, ocular surface and general), treatment effects, social, 
emotional, work and economic impact of glaucoma expressed by the participants. Two criteria were used to 
include any topic as a theme in the final analysis.
44
 The first criterion was that at least two participants had 
to make substantive comment on the topic in a single group. The second selection criterion was that the 
topic was discussed by at least one participant in more than one group. The themes were reviewed by the 
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authors and rephrased to develop new items. These items were added to the initial item pool which 
consisted of the extant items from the literature review.  
 
Identification of domains, item stem and response options 
On the basis of the comprehensive literature review, input from patient focus groups, semi-structured 
interviews and consensus between the researchers, ten domains important to patients with glaucoma were 
identified. The domains were activity limitation, mobility, visual symptoms, ocular surface symptoms, general 
symptoms, convenience, health concerns, emotional well-being, social well-being and economic issues. 
Item stem and response options for each of these ten domains were also formulated on the basis of a 
comprehensive literature review and consensus between the researchers (JK, KP, EL and EF). The item 
stem is simply the question that states the particular item, for example “How often do you experience…” 
Response options are a set of categories defined by descriptive terms provided to the participants to 
endorse the item,
45
 such as, “Never, Occasionally, Quite often, Very often.” The literature review was 
carried out to explore the evidence on optimally functioning item stem and response option across all the 
health specific PRO instruments which were developed or validated using Rasch analysis. Rasch analysis 





Item classification and selection  
Upon domain identification, items in the initial item pool were selected and classified under the ten domains 
on the basis of their colloquial meaning that represented the domain most accurately. A method of “binning 
and winnowing” was used to classify and refine items within each of the ten domains.  
 
Binning  
Binning is a systematic method of grouping (binning) items according to their meaning under a specific 
domain.
47
 For example, “reading small print” became a bin within the activity limitation domain. The goal for 
this process was to identify items that capture the meaning of the domain and to eliminate obviously 
redundant items. For example, “reading small writing” was similar to “reading small print” and was therefore 




Winnowing is a systematic method of reducing the large item pool to a representative set of items according 
to a set of inclusion and exclusion criteria.
47
 The following criteria were used for removing items from the 
initial item pool:  
(1) item inconsistent with the domain definition 
(2) item similar in meaning with other item(s) 
(3) item content too narrow to have wider applicability 




Expert review and revision of items  
After binning and winnowing, authors JK, KP, EF and EL systematically refined the item pool again. These 
authors are either internationally recognised experts in PRO development and validation or have experience 
in PRO development. The authors reassessed the clarity and appropriateness of all remaining items based 
on the four criteria outlined above. Items that were ambiguous or confusing were rephrased and any 
discrepancies that occurred between the authors were resolved by discussion.  
 
Cognitive interviews with patients  
Cognitive interviews were conducted to assess the clarity of instructions, items and response options prior 
to pilot testing of the instrument.
48
 These interviews also allowed us to assess whether the pilot instrument 
had adequate content coverage and the items were relevant to patients.  The 341 items were administered 
to each participant and any problematic items and particular comments by the participants were noted. 
Feedback from the cognitive interviews was incorporated and necessary changes were made.  
 
Results  
Identification of extant items from published PRO instruments 
Nineteen PRO instruments which were specifically developed for glaucoma patients were identified from the 
literature review (Table 1). A total of 530 items were extracted from the 19 instruments, out of which only 





Identification of items from a qualitative literature review 
A further literature review of peer-reviewed publications that reported qualitative research with glaucoma 
patients was also carried out to extract content which was not included in the extant PROs. Six publications 
were identified from which fourteen unique items were drawn.
3, 5, 6, 13, 49, 50
 
 
Focus groups and semi-structured interviews  
The demographic characteristics of the focus group and interview participants are presented in table 2. A 
total of 614 items were extracted from the focus groups and semi-structured interviews. Of these, 138 had 
already been identified in the extant PROs and qualitative literature review and therefore, 476 (77.5%) were 
unique items. Table 3 provides examples of items which were drawn from the focus groups and semi-
structured interviews.  
 
Item classification and selection 
A total of 737 items were identified from extant instruments, the literature review, focus groups and semi-
structured interviews. An initial item pool comprising 10 domains was organised using the binning method. 
Activity limitation (168) and health concerns (149) were the largest domains, while general symptoms (19), 
visual symptoms (31) and mobility (32) were the smallest domains. Data from the focus groups and semi-
structured interviews significantly increased the number of items in all of the domains (Figure 1).  
 
After four sessions of binning and winnowing, 388 items were removed, leaving 341 minimally 
representative, unique items distributed among the 10 domains (Table 4). Table 5 provides examples of 
items that were removed at the binning and winnowing stage. The domain “health concerns” had the highest 
number of items removed (70% from the initial pool removed) followed by activity limitation (48% removed). 
 
Domain question format and response option 
Table 5 shows the item stems and response options formulated for the ten domains. The generation of the 
item stem and response options were guided by empirical evidence on commonly occurring domains 
(activity limitation, mobility, symptoms, and emotional well-being). The review suggested that symptoms can 
be rated in three scales (frequency, severity and bothersome).
31
 Therefore, three different question formats 
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and response options were used (table 6). There was no or little evidence available for the three novel 
domains (convenience, health concerns and economic), so the item stem and response options were 
generated by the researchers. The literature review also suggested that four to five response options are 
optimal and thus our item pools utilized four or five response options across the ten domains (table 6).
30, 51
 A 
non-applicable option was also used when necessary. A preceding statement “Because of your glaucoma 
and its treatment…” was formulated for the overall item bank. The term ‘glaucoma’ was not defined further 
so as to appear inclusive for all people potentially completing the questions. By treatment we include people 
using medication or undergone laser or surgery for glaucoma.  
 
Expert review and revision of the items  
After binning and winnowing, the remaining 341 items were thoroughly reviewed by the authors for wording, 
fit to question format, and meaning. See table, supplement digital content file 1, which shows some 
examples of items that were rephrased in order to fit the domain question format.  
 
Cognitive interviews with patients and the pilot instrument 
After 10 cognitive interviews, the wordings of 4 items were modified and 1 item was added (Table, 
supplement digital content file 2). The participants did not have any issue with the clarity of instruction, item 
stem and response categories. Therefore, at the conclusion of the cognitive interviews the pilot instrument 
had 342 items. Table, supplement digital content file 3, provides some examples of items in the pilot 
instrument which were derived from the existing PRO instruments and patients’ input (focus groups or semi-
structured interviews).   
 
Discussion  
While many glaucoma-specific PRO instruments exist, there is not a single PRO that comprehensively 
measures QOL. Such an instrument is needed as an end-point for clinical research in order to provide a 
more comprehensive assessment of the disease or treatment impact from the perspective of the patient. 
Creating such an instrument is our overall aim and the starting point is to identify a comprehensive set of 
items within all QOL domains important to people with glaucoma. Hence, we adopted a systematic and 
multi-phased content development method to identify items.  
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A review of existing glaucoma-specific PRO instruments and associated literature can serve as a rich 
source of item content.
20, 52
 Therefore, we created an initial item pool from existing PROs and qualitative 
literature review. We surveyed PRO instruments that have been specifically developed and validated for 
patients with glaucoma and peer-reviewed qualitative publications that explored issues important to people 
with glaucoma. By restricting our review to glaucoma specific material, the possibility of content 
contamination by issues that are not relevant to patients with glaucoma might have been avoided.  
 
The initial item pool was supplemented by material derived from patients (focus groups and semi-structured 
interviews). The value of patient input in identifying content has been highlighted for several other vision-
specific instruments.
53-56
 This approach has allowed us to produce items that are important and relevant to 
people with glaucoma. In this study, the topic guide was designed specifically to identify new content (items) 
which was not covered by existing PRO instruments and the qualitative literature review thus ensuring that 
the item pools would cover the full range of glaucoma-specific QOL issues. It is also important to have a 
sufficient number of items and content coverage in a PRO or a particular domain to enable adequate 
measurement precision.
29, 57
 For example, the Glaucoma Symptoms Scale (GSS) has been found to 
possess inadequate measurement precision due to insufficient items and content coverage.
35
 Therefore, the 
interviews with patients were also targeted to explore, in more detail, issues in domains (i.e. health 
concerns, social and economic) which were under-represented in the initial item pool (Figure 1). Patients’ 
input also served to test content saturation of the ten domains; that is to determine when all possible items 
of importance to patients were identified so the item identification process could stop.  
 
Following content identification, the process of binning and winnowing provided a means to systematically 
classify items into different domains and the item pool to be refined. This method has been successfully 
used in developing and refining items during the development of the Patient-Reported Outcomes 
Measurement Information System item bank.
47, 58
 Here, a total of 530 items were identified from the extant 
PROs. However, the binning process revealed that many of these items were similar and therefore the total 
number of unique items was less than 50%. Furthermore, when the items from the qualitative literature 
review, focus groups and semi-structured interviews were added to the initial item pool, the total number 
was 737. This number was reduced to 341 minimally representative unique items after four sessions of 
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binning and winnowing (Table 3). One new item was added after the cognitive interviews. Therefore, the 
final pilot instrument had 342 items.  
 
Interestingly, the final item pool bears the majority of the items under “activity limitation”, “symptoms (visual, 
ocular surface and general)” and “emotional well-being”. Several other studies have also highlighted that 
restriction of daily living activities, treatment side-effects and emotional well-being are important issues to 
patients with glaucoma.
4-6, 17, 59
 These domains are also those with the most item coverage in existing 
glaucoma PRO instruments. The remaining 5 domains had little input from existing instruments, in 
particular, the health concerns, social and economic domains. This is an important finding as it 
demonstrates that existing instruments fail to capture of the range of QOL domains important to people with 
glaucoma.  Therefore, the item bank will provide new insight into the impact of glaucoma on QOL which has 
not been measured previously. This will be a valuable addition to clinical research which will lead to a better 
understand the efficacy of new and existing treatment options from the perspective of the patient. This will 
help clinicians to understand which treatment options best suit an individual patient’s needs.  
 
In the final process of refining the items, we modified many extant items from their original format (wording). 
We have taken this approach for two reasons: firstly, to make the items more uniform within each domain to 
simplify interpretation by the patients and secondly, to keep item wording as close as possible to the original 
utterances of the focus groups and semi-structured interview participants. This process should enhance 
participants’ understanding of the item meaning and simplify implementation of the item bank. One potential 
limitation of our approach is that the focus group participants were not probability sampled. The problem 
with probability sampling is that larger numbers of participants are required in order to cover the breadth of 
the condition as many “average” patients are recruited who tend to offer similar input. Instead, participants 
were purposively sampled to cover the breadth of the disease severity with a minimum number of 
participants. Given that focus groups and interviews were conducted in four centres in two countries, it is 
reasonable to expect these groups represent a wider glaucoma population.  
 
Noisy clinical trial endpoints measured from poor PRO instruments are a threat to research validity.
58
 It has 
become apparent that more reliable PRO instruments are necessary to improve efficiency, precision and 
accuracy of clinical trials outcomes. We expect the new glaucoma-specific QOL item bank to be a precise 
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and efficient instrument which will outperform the existing glaucoma-specific PRO instruments. The 
developmental stage of the project reported in this paper has utilised comprehensive item identification and 
item refinement methods. The next step will be to collect data on the items in the item bank and to use 
Rasch analysis to refine and calibrate items under each of the ten domains.
29
 The item bank will undergo 
rigorous validation and reliability testing before it is made available for use in clinical trials. Our group is 
currently developing item banks for all major ophthalmic diseases and conditions (the Eye-tem Bank).
37
 This 
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Figure 1: Bar diagram showing the number of unique items identified from the literature review and 
qualitative sessions (focus groups and semi-structured interviews). (AL = Activity limitation, MB = Mobility, 
VS = Visual symptoms, OS = Ocular surface symptoms, GS = General symptoms, CV = Convenience, HC = 




































Table 1: Glaucoma-specific PRO instruments used to extract items for the initial item pool  
 Instrument  No. of 
items 
Basis of original content 
development 
1 Ross et al (1984)
9 
16 Not reported 
2 Mills et al (1986)
8 
15 Literature review 
3 COMTOL - Barber et al (1997)
10 
50 Lay focus groups 
4 GSS - Lee et al (1998)
16
  10 Literature review/other PROs  
5 Viswanathan (1999)
19 
10 Literature review 
6 SIG - Janz et al (2001)
4
  43 Literature review 
7 Odberg et al (2001)
5 
33 Not reported  
8 Uenishi et al (2003)
12
  31 Literature review/other PROs 
9 GQL-15 - Nelson et al (2003)
25  
15 Literature review/other PROs 
10 TSS-IOP - Atkinson et al (2003)
13 
15 Literature review/other PROs/lay 
focus groups 
11 EDSQ - Nordman et al (2007)
15 
46 Expert interviews 
12 Dunker et al (2007)
11 
29 Not reported 
13 Glau-QOL - Bechetoille et al 
(2008)
14 
36 Literature review/ other PROs/ lay 
focus groups 
14 Glausat - Ruiz et al (2010)
18
 22 Expert/lay focus groups 
15 GSI - Walt et al (2011)
20 
32 Other instruments/ patients and 
clinicians input  
16 Adherence Questionnaire- 
Schwartz et al (2009)
21 
56 Literature/expert input and opinion 
17 Self-efficacy - Sleath et al 
(2010)
23 
35 Other PROs/peer-reviewed 
literature/ expert and patients input 
18 Outcome Expectation Scale- 
Sleath et al (2010)
23 
4 Other PROs/peer-reviewed 
literature/expert and patients input 
19 Burr et al (2007)
22
 32 Focus groups/other PROs/expert 
opinion 
PRO: Patient reported outcome  
COMTOL: Comparison of Ophthalmic Medication for Tolerability 
GSS: Glaucoma Symptom Identifier 
GQL-15: Glaucoma Quality of Life Questionnarie-15 
VFDQ: Visual Field Disability Questionnaire  
TSS-IOP: Treatment Satisfaction Survey of Intraocular Pressure 
SIG: Symptoms Impact Glaucoma Score  
EDSQ: Eye-drop Satisfaction Questionnaire 
Glau-QOL: Glaucoma Quality of Life  
Gluasat: Glaucoma Satisfaction Questionnaire  
































Gender; n (%)  
Female  38 (52.8%) 
Glaucoma type; n (%) 72 (100%) 
POAG 51 (70.8%) 
Secondary glaucoma 9 (12.5%) 
ACG 7 (9.7%) 
PXF 4 (5.6%) 
NTG 1 (1.4%) 
 Glaucoma severity (AGIS classification; n (%) 58 (100%) 
≤ Mild in better eye, ≤ moderate in worse eye 17 (29.3%) 
≤ Mild in better eye, ≥ Severe in worse eye 27 (46.6%) 
Moderate in better eye, ≥ Moderate in worse eye 7 (12.1%) 
≥ Severe (both) 6 (10.3%) 
Visual acuity (Better eye); LogMAR (Snellen equivalent)  
Median   0.1  (6/7.5) 
Range -0.2 to 1.30 (6/4 to 6/120) 
Visual  (worse eye;  LogMAR (Snellen equivalent)  
Median 0.2 (6/9.5) 
Range  -0.2 to PL (6/4 to  PL) 
Current management; n (%) 58 (100%) 
       Topical medications only 19 (32.8%) 
       Surgery with no topical medications  26 (44.8%)  
       Surgery with topical medications 7 (12.1%) 
       None 5 (8.6%) 
Types of surgery among the surgical group (%)  
       Selective laser trabeculoplasty 13% 
       Argon laser trabeculoplasty 5.1% 
       Trabeculectomy 38.5% 
       Trabeculectomy with mitomycin-C or 5-fluorouracil 23% 
       Molteno tube 5.1% 
Number of topical medications among the medication user group (%)  
       One 50% 
       Two 46.2% 
       Three 3.8% 
Types of topical medications (%)  
      Prostaglandin agonist  45% 
      Beta-blocker 27.5% 
      Carbonic anhydrase inhibitor 7.5% 
      Carbonic anhydrase inhibitor plus Beta-blocker 7.5% 
      Prostaglandin agonist plus Beta-blocker 5.0% 
      Prostaglandin agonist 2.5% 
      Muscarinic receptor agonist 2.5% 
      Selective alpha-2 adrenergic agonist 2.5% 
* Percentages for some variables may not equal 100% due to missing data 
POAG= Primary open angle glaucoma; ACG =Acute Angle closure glaucoma; PXF = Pseudo-exfoliation 
glaucoma; NTG = Normal tension glaucoma; AGIS = Advanced Glaucoma Intervention Study; Log MAR = 
Log of Minimum Angle of Resolution; PL = Light Perception   
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Table 3: Example of items extracted from the focus groups and semi-structured interviews 




Item stem  
“No, I can’t, I can’t, I can see what they [price 
labels] are, but I can’t read them you know” 
 
3 …reading price labels in 
shops  
“Ah, I found the last couple of weeks when 
I’ve been watching the television, in spite of 
the fact that the next program is something I 
want to watch, after some time my eyes feel 
tired and they feel sore. And I have had 
enough and I turn the box off – because I 
can’t cope” 
 
4 …watching television 
 
 
“..sunlight during the day there’s sun shining 
brightly you can’t see and then you go into, 
down the side of the building, there is 
shadow, then you notice a difference then”  
 
7 …seeing in bright sunlight 
And …difficulty seeing when 
going from bright sunlight to 
dark conditions 
“Yes, tiredness… I forget which drops I got, 
but the first drops I got originally, one of the 
side effects was tiredness”  
 
3 …tiredness 
“Because you can not squeeze the droppers 
and get about 8 drops out and it flushes over 
your face – things like that – and they can 
erode your ability to treat yourself. And I have 
spoken to people who don’t apply their own 
drops, they get the spouse…” 
 
4 …administering eyedrops 
“I used to work; I lost my job through my eye 
sight because I used to drive…” 






Table 4: Number of items in the item pool before and after binning and winnowing  
 
Domain  
AL MB VS OS GS 
 









88 20 18 22 15 39 45 49 23 22 341 
AL: Activity Limitation; MB: Mobility; VS: Visual Symptoms, OS: Ocular Surface Symptoms; 





Table 5: Example of items deleted at the binning and winnowing stage 
Item stem Domain Reason for removal  







Redundant item (captured by other 
items; “driving towards oncoming 
headlights” and “driving towards the 
sun” ) 




Redundant item (captured by other 
item; “noticing things to the left or the 
right of you while you are walking”)  
 
“discomfort in your eye after an 
eye operation due to stiches” 
 
Symptoms Narrow item (too specific and refers to 
discomfort due to stiches) and 
“discomfort in your eyes” already 
included 
 
“wish something could be done 
to cure glaucoma”  
 
 
Emotional Not really a measurable item, but the 
underlying issue is denial; “have trouble 
accepting that your eye problems are 
permanent” already included 
 
“felt weaker, less strong than I 




Confusing item (double barrelled; item 
can refer to both physical or emotional 
weakness) and “feel emotionally 
drained” already included 
 
“not being able to do things for 
as long as you want to, used 
to, e.g. reading” 
Health concern 
 
Inconsistent with domain definition 
(item does not refer to health related 
















































































Domain Item stem 
 Because of your glaucoma and its    
 treatment… 
Response options  
Activity limitation 
and Mobility  
 
 
How much difficulty do you have…..? 




How often do you experience….? 
 
Never to Very often 
How severe is the…? 
 
Not at all to Severe 
How much of a problem is/are the…? 
 
None to A lot  
Convenience How much trouble is…? 
 
None to Extreme 
Health concerns How concerned are you about…? Not at all to Extreme 
 
Emotional How often do you….? None of the time to All of the  time  
 
Social How much of a problem do you have 
with…? 
None to Unable to do because of 
my vision 
 





Figure 1:  
 
 
